For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Get the latest on Moderna’s Q3 earnings, analyst forecasts, COVID-19 vaccine sales impact, and what could shape MRNA’s stock ...

An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the ...

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ongoing phase IV study, which evaluated the updated version of its COVID-19 ...